Related Experiment Video
Updated: May 23, 2026
05:16
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Biomarker changes during acute heart failure treatment
Brent Boyer1, Kimberly W Hart, Matthew I Sperling
1Medical University of South Carolina, Charleston, SC, USA.
Congestive Heart Failure (Greenwich, Conn.)
|March 22, 2012
Summary
Biomarker levels for mid-regional-pro-atrial natriuretic peptide (MR-proANP), mid-regional-pro-adrenomedullin (MR-proADM), and C-terminal-pro-endothelin-1 (CT-pro-ET-1) change within 24 hours of acute decompensated heart failure therapy. These changes may offer objective evidence of treatment efficacy.
Area of Science:
- Cardiology
- Biomarker Research
- Acute Heart Failure Management
Background:
- Acute decompensated heart failure (ADHF) requires objective measures of treatment efficacy.
- Biomarkers can potentially indicate treatment response and facilitate early hospital discharge.
Purpose of the Study:
- To investigate changes in specific biomarkers during the initial 24 hours of ADHF therapy.
- To assess the dynamic changes of MR-proANP, MR-proADM, and CT-pro-ET-1 in ADHF patients.
Main Methods:
- Prospective study of 48 ADHF patients meeting modified Framingham criteria.
- Collection of clinical data and serum/plasma biomarker levels at baseline, 2-4 hours, and 12-24 hours.
- Statistical analysis of biomarker concentration changes using Fisher exact and Kruskal-Wallis tests.
Main Results:
- Mid-regional-pro-atrial natriuretic peptide (MR-proANP) showed changes in 36% of patients within 2-4 hours.
- By 12-24 hours, similar proportions of patients exhibited changes in MR-proANP (47%), MR-proADM (41%), and CT-pro-ET-1 (49%).
- All three biomarkers demonstrated measurable changes within 24 hours of ADHF treatment initiation.
Conclusions:
- Patients with ADHF experience measurable changes in MR-proANP, MR-proADM, and CT-pro-ET-1 within 24 hours of therapy.
- Further research is warranted to explore the association of these biomarker changes with clinical course and outcomes.
- These biomarkers may play a role in risk-stratification for ADHF patients.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...